Kaiser Permanente regional drug formulary (NorCal/SoCal) Medi-Cal (California Medicaid) excluded weight-loss GLP-1 receptor agonists effective January 1, 2026 meaning Zepbound and Wegovy are no longer covered for obesity under Medi-Cal
Most people experience some digestive discomfort
doi:10.1016/j.bbadis.2024.167089
This shift reflects intensifying competition, evolving patient expectations, biopharma companies desire to expand access for the patients they serve, and policy momentum aimed at lowering drug prices and increasing transparency
Neohesperidin (NHP) can inhibit macrophage migration into target tissues and decrease pro-inflammatory cytokine levels, including TNF-, IL-1, IL-6, and COX-2, at both mRNA and protein levels, exceeding that of mesalazine at similar concentrations (173)
"Combination therapy with doxazosin and finasteride for benign prostatic hyperplasia in patients with lower urinary tract symptoms and a baseline total prostate volume of 25 ml or greater"
